Lianbio (LIAN)

They are a global, science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. They have purposefully designed their organization to successfully execute on their vision by identifying, sourcing, developing and commercializing product candidates and partnering with highly innovative biopharmaceutical companies around the world. They are establishing an international infrastructure to position ourselves as a partner of choice with a platform to provide access to their target markets. Their model leverages a number of key elements, including transformative in-licensing, development and commercialization approaches that they believe will enable them to deliver innovative therapeutic solutions to patients in Greater China, including Mainland China, Hong Kong, Taiwan and Macau, and other Asian markets. Their deep relationships with their founder, Perceptive Advisors (“Perceptive”), as well as their broader investor base, position them to access and capture attractive business development opportunities. They have also entered into high-value strategic collaborations with Pfizer Inc. (“Pfizer”), which offers optionality to leverage its broad reach and commercial infrastructure in Greater China, and BridgeBio Pharma LLC (“BridgeBio”), which provides preferential access to an innovative pipeline of more than 20 product candidates in development.

Industry
Pharmaceutical Preparations

CEO	CFO
-

Employees	Founded
87	2019

Address: 103 Carnegie Center Drive, Suite 215 Princeton, Nj 08540

Telephone: (609) 486-2308

Web page: http://www.lianbio.com

First Trade Date	11/2/2021
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the LIAN share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: Goldman Sachs

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
Goldman Sachs/ Jefferies/ BofA Securities
CO-Managers
Raymond James